Gabapentin Raw Material Gabapentin Powder

CAS:60142-96-3

MF: C9H17NO2

MW: 171.24

EINECS: 262-076-3

Specification​: 99% min Gabapentin Powder

Sample: Gabapentin Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Gabapentin Powder Usage and Synthesis.

1、Post herpes infection neuralgia: for the treatment of post herpes neuralgia in adults.

2、Epilepsy: for the adjuvant treatment of partial seizures with or without secondary generalised seizures in adults and children over 12 years of age. It can also be used for the adjuvant treatment of partial seizures in children aged 3-12 years.

Uses and functions of Gabapentin.

Gabapentin is used for postherpetic neuralgia; as an adjunct to the treatment of partial seizures with or without secondary generalised seizures in adults and children over 12 years of age. It is also used as an adjunctive treatment for partial-onset seizures in children 3 to 12 years of age.

Used as add-on therapy in patients with epilepsy with limited seizures not satisfactorily controlled or tolerated by conventional antiepileptic drugs, and in patients with epilepsy with limited seizures with secondary generalisation. Anxiolytics.

Pharmacological Effects of Gabapentin Raw Materials .

Gabapentin is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA) but has no effect on GABA binding, uptake or degradation.

1. The mechanism of the anticonvulsant effect of gabapentin is not clear, but animal tests suggest that, similar to other marketed anticonvulsant drugs, gabapentin can suppress seizures. The results of maximal electroshock test in mice and rats, benztetrazolium seizure test and other animal tests (such as hereditary epilepsy model, etc.) suggest that gabapentin has an antiepileptic effect, but the relevance of these epileptic models to human beings is not yet clear.

2. Gabapentin is structurally related to the neurotransmitter GABA, but does not interact with GABA receptors; it is neither metabolically converted to GABA or GABA agonist, nor is it an inhibitor of GABA uptake or degradation.

Radioligand binding assays have found that gabapentin at concentrations up to 100 μM has no affinity for many common receptor sites, including benzodiazepine receptors, glutamate receptors, NMDA receptors, quisqualate receptors, hippuric acid receptors, fenugreek-insensitive or -sensitive aminoglycolic acid receptors, α1, α2, or β receptors, adenosine A1 or A2 receptors, M or N receptor, dopamine D1 or D2 receptor, H1 receptor, 5-hydroxytryptamine S1 or S2 receptor, opioid μ, δ, or k receptor, voltage-sensitive calcium channel sites labelled with nilandipine or diltiazem, and voltage-sensitive sodium channel sites labelled with frog toxin A 20-α-benzoate. Since several commonly used tests in evaluating the effects of drugs on NMDA receptors have yielded opposite results, there is not yet any unified understanding of the effects of gabapentin on NMDA receptors.

3. In vitro studies have shown that the binding sites of gabapentin in the rat brain are distributed in the neocortex and hippocampus, and its high-affinity binding protein has been shown to be an auxiliary subunit of voltage-activated calcium channels, and its related function has not yet been elucidated.

Production method of Gabapentin Raw Powder .

Reaction of monomethyl 1,1-cyclohexane-7,acid (I) with ethyl chloroformate dissolved in acetone containing triethylamine and sodium azide dissolved in water, the product (II) formed was refluxed in 20% hydrochloric acid for 3h to give gabapentin.